about
Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transferAsthma-related deathsMapping genetic variants associated with beta-adrenergic responses in inbred miceBronchodilatory and anti-inflammatory effects of ASM-024, a nicotinic receptor ligand, developed for the treatment of asthmaAgonist-directed desensitization of the β2-adrenergic receptorChallenges in the pharmacological treatment of geriatric asthma.Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonistsβ-Agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent.Wnt/β-catenin signaling modulates human airway sensitization induced by β2-adrenoceptor stimulation.Human trachealis and main bronchi smooth muscle are normoresponsive in asthma.Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial.Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β(2) -adrenoceptors and exacerbates lung inflammation in mice.Local anaesthetic medication for the treatment of asthma.Lactic acidosis and diastolic hypotension after intermittent albuterol nebulization in a pediatric patient.The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studyPediatric asthma mortality and hospitalization trends across Asia pacific: relationship with asthma drug utilization patterns.Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.Formoterol in the management of chronic obstructive pulmonary disease.Agonizing over agonism: should asthmatics turn their beta-receptors on or off?Adverse effects of salmeterol in asthma: a neuronal perspective.Emergency presentation and management of acute severe asthma in children.Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.Airway smooth muscle modulation and airway hyper-responsiveness in asthma: new cellular and molecular paradigms.An update on the use of indacaterol in patients with COPD.New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.(R)-salbutamol in the treatment of asthma and chronic obstructive airways disease.Are beta2-agonists responsible for increased mortality in heart failure?Function and mechanisms of TSLP/TSLPR complex in asthma and COPD.cAMP regulation of airway smooth muscle function.A comparison of heart rate changes associated with levalbuterol and racemic albuterol in pediatric cardiology patients.Asthma medications should be available for over-the-counter use: pro.Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.Addressing the misdiagnosis of asthma in adults: where does it go wrong?The importance of β2-agonists in myocardial infarction: Findings from the Eastern Danish Heart Registry.Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction.Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males.Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases.
P2860
Q24804996-2F5BD453-8BD4-45C2-B8CC-FEBF75AA19F4Q28073233-124129AD-EB5D-4D28-9093-7A2BE41BF778Q28481719-CEEBCADA-7BAD-47E1-8256-6C5DFE3453C8Q28539013-616F7D89-7CF5-4BB4-BFCC-4AB46E117CC7Q28740731-0CF11A68-2B9A-4E52-AAB3-7943D36F0975Q30251770-19CA7A4E-C54D-47A2-8B31-FBFC99BDC7DCQ33156631-30CFF39B-68B5-4779-8EDE-6CE83922ABE4Q34044729-6B9264CA-4264-4293-AD0B-F8E680F927E5Q34434700-100643D9-9195-4F7E-BA19-822C0DD97133Q35618484-658E979F-7813-4F55-99DC-53D51623A409Q35686996-29FA30A7-9441-438B-A8AA-AD1B3C91B682Q35822146-A5E5F4FE-F4AD-4B45-AAE6-0F836A5323DCQ36147356-C6082194-A5AE-4723-A723-CEDC9F40E3BCQ36165908-46009180-6498-4DF2-B322-760E0B239D1CQ36379061-9288E2D1-FA51-4DF8-952A-48913F709670Q36477727-3E76C26D-85EB-43CD-9EE3-85BEC37BDB8EQ36834471-D4787ACF-EA7D-402B-A44A-EEE6BBBEE66CQ36892408-E4527BF9-2505-4DF2-8AAC-3BC86EEBDFF4Q37070307-087D838E-E882-4766-A389-0D5CD86AFF5FQ37114730-637E2F41-1B28-4850-8CAD-B720CAC265B3Q37314867-E60BDE71-0C6D-486C-B6A5-04B9DAC2CF97Q37357922-24B4D076-A656-431A-A6AA-82E08CFDCFF5Q37487619-F3F0F6A5-7AFA-474C-B4A8-BA9511276586Q37754516-F848AA24-DF2C-41DF-9E7A-50CF0ACC2342Q37808058-78B08F9E-DF67-44F9-B007-0B9B2BE7EE82Q37822833-805DED0A-5672-4E6E-AEB8-6A855C08F6EFQ37859789-2A59E1AC-A121-4FD4-85EE-02F91A97A50BQ37906050-F2F3A02C-B5D6-4F69-8C49-49779D4527FCQ37968330-391B7C90-631F-479A-884D-5B9E90696CEAQ38013462-FDCD5AD2-5CBA-472B-A63A-1292E0131BC7Q38101270-0891F03F-2696-4DCB-B81D-751B6930B772Q38223151-DF5C4EFA-7394-4DD1-80B1-5DAFD0A7ADFFQ38272007-7FA5EA81-D9FA-407E-B1A9-71669409EE89Q38947467-2FF0999D-EF39-4812-BAF8-87505A68BD68Q38965989-3A942AB8-4F8E-4C9E-BFC1-68CB1C7A2DFCQ39183200-61105850-6440-413A-AB7E-BA12CB6250B2Q39869502-40779BBD-7FA7-4970-B376-59B667FB33A3Q40771974-2300D8FF-079C-4B4C-A9AE-0B28B2F94352Q42010395-8FFB8F5E-E434-433B-84D9-D1B8A0B1007DQ42331967-49F071CE-24FE-4143-AEC7-BA28C1129FCB
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Adverse effects of beta-agonists.
@ast
Adverse effects of beta-agonists.
@en
type
label
Adverse effects of beta-agonists.
@ast
Adverse effects of beta-agonists.
@en
prefLabel
Adverse effects of beta-agonists.
@ast
Adverse effects of beta-agonists.
@en
P356
P1476
Adverse effects of beta-agonists.
@en
P2093
Malcolm R Sears
P304
P356
10.1067/MAI.2002.129966
P407
P433
P577
2002-12-01T00:00:00Z